Lilly, Alphabet, Amazon Earnings & Job Market Update
- The stock market is well-positioned to bounce next week if the heavyweight companies set to report earnings deliver strong numbers, CNBC's jim Cramer said Friday.
- That's because the market ended the week on a subdued note, the "Mad Money" host said, after the S&P 500 finished in the red for three straight days.
- The busy week wastes no time getting underway,with Disney reporting on Monday and talk of CEO succession in the air.Cramer's Charitable Trust, the portfolio used by the CNBC...
The stock market is well-positioned to bounce next week if the heavyweight companies set to report earnings deliver strong numbers, CNBC’s jim Cramer said Friday.
That’s because the market ended the week on a subdued note, the “Mad Money” host said, after the S&P 500 finished in the red for three straight days.
The busy week wastes no time getting underway,with Disney reporting on Monday and talk of CEO succession in the air.Cramer’s Charitable Trust, the portfolio used by the CNBC Investing Club, threw in the towel on its Disney position in November after a prolonged period of stagnant performance. “There was always some division that held it back. I don’t know which it is indeed this time. You never do,” Cramer said.
On tuesday, we’ll get the latest from names including Pfizer, PepsiEli Lilly Stock: Jim Cramer’s Watchlist and 2026 Outlook
Table of Contents CNBC’s Jim Cramer added Eli Lilly (LLY) to his watchlist on Wednesday, January 28, 2026, citing the importance of upcoming clinical trial data for its GLP-1 drugs, rather than solely focusing on quarterly earnings. As of January 31, 2026, Eli Lilly shares have decreased approximately 3.5% year-to-date. Cramer indicated he will closely monitor Eli Lilly for updates on its GLP-1 portfolio trials, believing this data holds greater potential to influence the stock price than the company’s financial reports. He stated this during his “Lightning Round” segment on CNBC’s Squawk on the Street program. This focus reflects the broader market anticipation surrounding GLP-1 receptor agonists, a class of drugs initially developed for type 2 diabetes but increasingly recognized for their weight loss benefits. Eli lilly is a key player in this space, competing with Novo Nordisk. Eli Lilly’s GLP-1 portfolio includes drugs like Mounjaro (tirzepatide) and Zepbound (also tirzepatide, but approved for weight loss). These medications work by mimicking the effects of the GLP-1 hormone,which regulates appetite and blood sugar levels. Detail: Mounjaro received FDA approval for the treatment of type 2 diabetes in may 2022, and Zepbound received FDA approval for chronic weight management in December 2023. FDA Approval of Zepbound. Ongoing trials are investigating the potential of these drugs for additional indications, such as cardiovascular disease and sleep apnea. Example: In a phase 3 trial, Zepbound demonstrated an average weight loss of approximately 18% in participants over 72 weeks. Lilly’s Zepbound (tirzepatide) Demonstrated Significant and Sustained Weight Loss in Phase 3 SURMOUNT-2 Trial As of January 31, 2026, Eli Lilly’s stock (LLY) has experienced a year-to-date decline of roughly 3.5%. This performance is influenced by factors including broader market conditions, investor sentiment regarding pharmaceutical valuations, and anticipation of clinical trial results. Detail: The pharmaceutical sector, as a whole, has faced increased scrutiny regarding drug pricing and potential regulatory changes, contributing to some volatility in stock prices. Example: On January 27, 2026, LLY closed at $685.23 per share. Eli Lilly Stock Quote (Yahoo Finance). This represents a decrease from its year-end 2025 closing price of $709.88.Jim Cramer’s Rationale for Adding Eli Lilly
Eli Lilly’s GLP-1 Drug Portfolio
Eli Lilly Stock Performance (Year-to-Date 2026)